Literature DB >> 30771762

Leptomeningeal dissemination: a sinister pattern of medulloblastoma growth.

Daniel W Fults1, Michael D Taylor2, Livia Garzia3.   

Abstract

Leptomeningeal dissemination (LMD) is the defining pattern of metastasis for medulloblastoma. Although LMD is responsible for virtually 100% of medulloblastoma deaths, it remains the least well-understood part of medulloblastoma pathogenesis. The fact that medulloblastomas rarely metastasize outside the CNS but rather spread almost exclusively to the spinal and intracranial leptomeninges has fostered the long-held belief that medulloblastoma cells spread directly through the CSF, not the bloodstream. In this paper the authors discuss selected molecules for which experimental evidence explains how the effects of each molecule on cell physiology contribute mechanistically to LMD. A model of medulloblastoma LMD is described, analogous to the invasion-metastasis cascade of hematogenous metastasis of carcinomas. The LMD cascade is based on the molecular themes that 1) transcription factors launch cell programs that mediate cell motility and invasiveness and maintain tumor cells in a stem-like state; 2) disseminating medulloblastoma cells escape multiple death threats by subverting apoptosis; and 3) inflammatory chemokine signaling promotes LMD by creating an oncogenic microenvironment. The authors also review recent experimental evidence that challenges the belief that CSF spread is the sole mechanism of LMD and reveal an alternative scheme in which medulloblastoma cells can enter the bloodstream and subsequently home to the leptomeninges.

Entities:  

Keywords:  EMT = epithelial-to-mesenchymal transition; HGF = hepatocyte growth factor; LMD = leptomeningeal dissemination; MT1-MMP = membrane type-1 matrix metalloproteinase; PI3K = phosphatidylinositol-3 kinase; Tsp-1 = thrombospondin-1; VEGF = vascular endothelial growth factor; hematogenous metastasis; leptomeningeal dissemination; medulloblastoma; oncology

Year:  2019        PMID: 30771762     DOI: 10.3171/2018.11.PEDS18506

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  9 in total

Review 1.  Medulloblastomics revisited: biological and clinical insights from thousands of patients.

Authors:  Volker Hovestadt; Olivier Ayrault; Fredrik J Swartling; Giles W Robinson; Stefan M Pfister; Paul A Northcott
Journal:  Nat Rev Cancer       Date:  2019-12-09       Impact factor: 69.800

2.  Ommaya Reservoir Insertion: A Technical Note.

Authors:  Stephen T Magill; Winward Choy; Minh P Nguyen; Michael W McDermott
Journal:  Cureus       Date:  2020-04-18

Review 3.  Recent advances in SHH medulloblastoma progression: tumor suppressor mechanisms and the tumor microenvironment.

Authors:  Lukas Tamayo-Orrego; Frédéric Charron
Journal:  F1000Res       Date:  2019-10-29

4.  Development of a High-throughput Agar Colony Formation Assay to Identify Drug Candidates against Medulloblastoma.

Authors:  Mohammed Sedeeq; Ahmed Maklad; Nuri Gueven; Iman Azimi
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-05

5.  3D spheroid models of paediatric SHH medulloblastoma mimic tumour biology, drug response and metastatic dissemination.

Authors:  Sophie J Roper; Franziska Linke; Paul J Scotting; Beth Coyle
Journal:  Sci Rep       Date:  2021-02-19       Impact factor: 4.379

6.  Inhibition of Rho-Associated Kinase Suppresses Medulloblastoma Growth.

Authors:  Cecilia Dyberg; Teodora Andonova; Thale Kristin Olsen; Bertha Brodin; Marcel Kool; Per Kogner; John Inge Johnsen; Malin Wickström
Journal:  Cancers (Basel)       Date:  2019-12-26       Impact factor: 6.639

7.  Calcium Signalling in Medulloblastoma: An In Silico Analysis of the Expression of Calcium Regulating Genes in Patient Samples.

Authors:  Ahmed Maklad; Mohammed Sedeeq; Michael J G Milevskiy; Iman Azimi
Journal:  Genes (Basel)       Date:  2021-08-27       Impact factor: 4.096

8.  Medulloblastoma uses GABA transaminase to survive in the cerebrospinal fluid microenvironment and promote leptomeningeal dissemination.

Authors:  Vahan Martirosian; Krutika Deshpande; Hao Zhou; Keyue Shen; Kyle Smith; Paul Northcott; Michelle Lin; Vazgen Stepanosyan; Diganta Das; Jan Remsik; Danielle Isakov; Adrienne Boire; Henk De Feyter; Kyle Hurth; Shaobo Li; Joseph Wiemels; Brooke Nakamura; Ling Shao; Camelia Danilov; Thomas Chen; Josh Neman
Journal:  Cell Rep       Date:  2021-06-29       Impact factor: 9.995

9.  Elevated Kir2.1/nuclear N2ICD defines a highly malignant subtype of non-WNT/SHH medulloblastomas.

Authors:  Yan-Xia Wang; Haibo Wu; Yong Ren; Shengqing Lv; Chengdong Ji; Dongfang Xiang; Mengsi Zhang; Huimin Lu; Wenjuan Fu; Qing Liu; Zexuan Yan; Qinghua Ma; Jingya Miao; Ruili Cai; Xi Lan; Bin Wu; Wenying Wang; Yinhua Liu; Dai-Zhong Wang; Mianfu Cao; Zhicheng He; Yu Shi; Yifang Ping; Xiaohong Yao; Xia Zhang; Peng Zhang; Ji Ming Wang; Yan Wang; Youhong Cui; Xiu-Wu Bian
Journal:  Signal Transduct Target Ther       Date:  2022-03-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.